These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 15485339

  • 1. Pneumococcal vaccine development.
    Poolman JT.
    Expert Rev Vaccines; 2004 Oct; 3(5):597-604. PubMed ID: 15485339
    [Abstract] [Full Text] [Related]

  • 2. Post-marketing effectiveness of Prevnar [pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein)] and implications for adult immunization.
    Parijs BA, Malinoski FJ.
    Mech Ageing Dev; 2004 Feb; 125(2):147-8. PubMed ID: 15037021
    [Abstract] [Full Text] [Related]

  • 3. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
    Albrich WC, Baughman W, Schmotzer B, Farley MM.
    Clin Infect Dis; 2007 Jun 15; 44(12):1569-76. PubMed ID: 17516400
    [Abstract] [Full Text] [Related]

  • 4. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults.
    Metlay JP, Fishman NO, Joffe M, Edelstein PH.
    Vaccine; 2006 Jan 23; 24(4):468-75. PubMed ID: 16125826
    [Abstract] [Full Text] [Related]

  • 5. Pneumococcal conjugate vaccines--a European perspective.
    Reinert RR.
    Int J Med Microbiol; 2004 Oct 23; 294(5):277-94. PubMed ID: 15532987
    [Abstract] [Full Text] [Related]

  • 6. The safety of 7-valent pneumococcal conjugate vaccine.
    Ghaffar F.
    Expert Opin Drug Saf; 2005 Jul 23; 4(4):631-6. PubMed ID: 16011442
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis.
    Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF.
    Pediatrics; 2009 Jun 23; 123(6):e1103-10. PubMed ID: 19482744
    [Abstract] [Full Text] [Related]

  • 8. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL, Chiu SS, Chow FK, Mak GC, Lau YL.
    Vaccine; 2007 Sep 28; 25(39-40):6837-41. PubMed ID: 17714837
    [Abstract] [Full Text] [Related]

  • 9. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2005 Sep 16; 54(36):893-7. PubMed ID: 16163262
    [Abstract] [Full Text] [Related]

  • 10. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.
    Toltzis P, Jacobs MR.
    Infect Dis Clin North Am; 2005 Sep 16; 19(3):629-45. PubMed ID: 16102653
    [Abstract] [Full Text] [Related]

  • 11. Immunogenic protein contaminants in pneumococcal vaccines.
    Yu J, Briles DE, Englund JA, Hollingshead SK, Glezen WP, Nahm MH.
    J Infect Dis; 2003 Mar 15; 187(6):1019-23. PubMed ID: 12660950
    [Abstract] [Full Text] [Related]

  • 12. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.
    Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, Patterson S, van Alphen AJ, Bonten MJ.
    Neth J Med; 2008 Oct 15; 66(9):378-83. PubMed ID: 18990781
    [Abstract] [Full Text] [Related]

  • 13. Pneumococcal conjugate vaccines. A review.
    Galiza EP, Heath PT.
    Minerva Med; 2007 Apr 15; 98(2):131-43. PubMed ID: 17519855
    [Abstract] [Full Text] [Related]

  • 14. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN, Austrian R.
    Clin Infect Dis; 2007 Apr 15; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract] [Full Text] [Related]

  • 15. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
    Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L.
    Pediatr Infect Dis J; 2009 Apr 15; 28(4 Suppl):S109-18. PubMed ID: 19325447
    [Abstract] [Full Text] [Related]

  • 16. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?
    van Kempen MJ, Vermeiren JS, Vaneechoutte M, Claeys G, Veenhoven RH, Rijkers GT, Sanders EA, Dhooge IJ.
    Int J Pediatr Otorhinolaryngol; 2006 Feb 15; 70(2):275-85. PubMed ID: 16140397
    [Abstract] [Full Text] [Related]

  • 17. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.
    Vaccine; 2006 Jul 17; 24(29-30):5690-9. PubMed ID: 16735083
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L.
    Pediatr Infect Dis J; 2009 Apr 17; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [Abstract] [Full Text] [Related]

  • 19. Protection of the elderly from pneumococcal pneumonia with a protein-based vaccine?
    Briles DE.
    Mech Ageing Dev; 2004 Feb 17; 125(2):129-31. PubMed ID: 15037017
    [Abstract] [Full Text] [Related]

  • 20. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.
    Ortqvist A, Henckaerts I, Hedlund J, Poolman J.
    Vaccine; 2007 Mar 22; 25(13):2445-50. PubMed ID: 17052816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.